KOSDAQBiotech & Pharma066700

Theragen Etex

₩2,025▲ 1.25%2026-11-18 close
Market Cap
₩74.3B
Turnover
₩78,739,947
Volume
40K
Shares out.
36.7M
PER
—
PBR
0.6×
EPS
-₩86
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Three Years of Revenue Growth, Narrowing Margins

Theragen Etex's revenue has grown for three straight years through 2025, but its operating margin slipped from 5.4% in 2022 to 3.8% in 2025.

  1. 1

    Revenue reached KRW 271.6 billion in 2025, the largest year of 2022–2025, and has risen for three straight years since 2023.

  2. 2

    Operating profit fell 18.3% to KRW 10.2 billion in 2025, and the 3.8% operating margin is the lowest of 2022–2025.

  3. 3

    Net income attributable to controlling shareholders returned to KRW 10.6 billion in 2025, yet the last four quarters total a KRW 4.2 billion net loss attributable to controlling shareholders.

  4. 4

    Pharmaceutical operations made up 94.4% of first-half 2026 consolidated revenue, and the debt ratio fell to 61.9% at end-2025 from 81.5% in 2024.

  5. 5

    Q3 2026 revenue rose 2.1% year on year to KRW 70 billion, while operating profit fell 14.8% year on year to KRW 1.66 billion.

02

Business structure

Theragen Etex was founded in September 1990 as a drug maker and distributor and listed on KOSDAQ in May 2004. In the first half of 2026, pharmaceutical operations accounted for KRW 130 billion of KRW 137.8 billion in consolidated revenue, or 94.4%.

That figure includes KRW 41.6 billion in prescription-drug merchandise sales from Lead Pharm, a consolidated subsidiary, equal to 30.2% of consolidated revenue. Drug production in 2025 was KRW 203.3 billion, and 87 licensed products with confirmed 2025 output accounted for KRW 156.2 billion, or 76.8%.

Key products include Pravicen (KRW 12.5 billion of output), Mosapit 5 mg (KRW 10.8 billion), Nexon 20 mg (KRW 10.4 billion), Aclpen (KRW 9.8 billion) and Atocen 10 mg (KRW 7.6 billion), and the top ten products together made up KRW 77.3 billion, or 49.5% of consolidated output.

By therapeutic class, anti-ulcer agents led with KRW 35.5 billion, followed by antiarteriosclerotics at KRW 22 billion and antipyretic, analgesic and anti-inflammatory agents at KRW 20.6 billion. Tablets and capsules made up 94.7% of output.

Sales run mainly through a contract sales organization division, and the company is expanding hospital sales and partnerships in Southeast Asia and Latin America.

The group also includes a precision genomics business, an anticancer drug-development affiliate, a prenatal genetic diagnostics affiliate, and a pharmacy and hospital distribution affiliate.

Consolidated revenue remains centered on pharmaceuticals, and the company has set a goal of entering the top tier of the domestic pharmaceutical market.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩68.6B₩2B2.8%
2025Q4₩69B₩4.2B6.1%
2026Q1₩68.5B₩1.9B2.8%
2026Q2₩69.3B₩2.6B3.8%
2026Q3₩70B₩1.7B2.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩193.4B₩10.3B₩9.6B5.4%6.7%56.4%
2023₩221.7B₩11.6B₩28.4B5.2%20.9%59.0%
2024₩249.6B₩12.5B-₩41B5.0%−36.5%81.5%
2025₩271.6B₩10.2B₩10.6B3.8%7.6%61.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a filed basis, annual revenue rose from KRW 193.4 billion in 2022 to KRW 221.7 billion in 2023 (up 14.7%), KRW 249.6 billion in 2024 (up 12.6%) and KRW 271.6 billion in 2025 (up 8.8%). Revenue has increased for three consecutive years from 2023, and the pace of growth slowed each year.

Operating profit rose from KRW 10.3 billion in 2022 to KRW 11.6 billion in 2023 (up 11.7%) and KRW 12.5 billion in 2024 (up 8.1%), then fell 18.3% to KRW 10.2 billion in 2025. The operating margin moved from 5.4% in 2022 to 5.2%, 5.0% and 3.8% in 2025, so margins narrowed while sales expanded.

Net income attributable to controlling shareholders rose to KRW 9.56 billion in 2022 and KRW 28.4 billion in 2023 (up 196.9%), then turned to a KRW 41 billion loss in 2024 before returning to KRW 10.6 billion profit in 2025.

Net income including non-controlling interests was a KRW 39.3 billion loss in 2024, smaller than the controlling-shareholder loss, which points to a non-controlling stake that was profitable that year.

Operating cash flow was KRW 9.59 billion in 2022, KRW 12.1 billion in 2023 and KRW 1.79 billion in 2024, before recovering to KRW 11 billion in 2025. The debt ratio rose from 56.4% in 2022 and 59.0% in 2023 to 81.5% in 2024, then eased to 61.9% in 2025.

At end-2025, total equity was KRW 159.2 billion, of which KRW 139 billion belonged to controlling shareholders, and total liabilities were KRW 98.5 billion. Quarterly, operating profit went from KRW 1.95 billion in Q3 2025 to KRW 4.24 billion in Q4 2025, a 117.2% quarter-on-quarter rise on revenue of KRW 69 billion.

In Q1 2026, revenue was KRW 68.5 billion (down 0.6% quarter on quarter), operating profit was KRW 1.94 billion (down 54.1%), and the controlling-shareholder net loss was KRW 3.74 billion.

Q2 2026 operating profit recovered to KRW 2.65 billion (up 36.1%), and Q3 2026 revenue reached KRW 70 billion, extending growth to two consecutive quarters, while Q3 operating profit fell 37.2% quarter on quarter to KRW 1.66 billion. The last four quarters total a controlling-shareholder net loss of KRW 4.2 billion. The filed figures alone do not explain the sharp rise in Q4 2025 operating profit.

05

Industry analysis

Domestic pharmaceutical conditions are tightening on profitability. One report noted that new drug approvals in Q3 2026 fell 15% year on year. The first round of the national drug price re-evaluation by the Health Insurance Review and Assessment Service is a particularly heavy variable for Theragen Etex.

The first-round target covers 116 insurance product codes, each tied to a different ingredient group, and the 87 licensed products with confirmed 2025 output account for KRW 156.2 billion, or 76.8% of the company's drug production.

Major products outside the first list, such as three Expera items with KRW 10.8 billion of 2025 output, remain in later rounds. A separately reported price cut covered 80 products with an average reduction of 4.6%.

On the other side, Seoul Credit Rating and Information described the stable pharmaceutical business as a base for responding to growth opportunities in the generics market, and cited the shift toward specialized manufacturing as an opportunity.

On production, average utilization at the Ansan plant reached 98.33% in the first half of 2026, which raises the need for added capacity. The company has referred to a plant expansion and is reviewing a second factory, and it has set goals of entering the top tier and the top 30 of the domestic pharmaceutical market.

06

Outlook

The company has laid out three priorities. First, it plans to use proceeds from the third-party share issuance of KRW 13 billion disclosed in February 2026 and KRW 5 billion of convertible bonds issued to its CEO for debt repayment and facility investment.

Second, it is pursuing a sale of its stake in an anticancer drug-development affiliate to realize long-held unrealized gains and improve its financial structure, and part of the proceeds is reported to go toward plant expansion. Third, it is reviewing a second factory, although this has not been finalized.

At the March 27, 2026 general shareholders meeting, changes to the articles of incorporation, including the introduction of interim dividends, were approved by special resolution, and one outside director was newly appointed, raising the outside director ratio to 28.6%.

The cancellation of 469,056 treasury shares, with a listing change scheduled for October 27, 2026, reduces the number of shares outstanding. On products, the company has pursued a strategy of growing Aclpen and Mosapit into blockbuster items with annual sales above KRW 10 billion.

The outcome of the drug price re-evaluation, the pace of debt repayment and the timing of plant expansion will shape future results. The 2026 annual report will show the fourth-quarter 2026 results and the use of proceeds.

07

Valuation

PER
—
PBR
0.6×
ROE
-3.4%
EPS
-₩86
BPS
₩3,326
Dividend per share
₩0

Valuation can be viewed through earnings and book value. Because the last four quarters show a net loss, a price-to-earnings ratio cannot be calculated, and earnings-based multiples are hard to compare with the sector. On a book-value basis, the price-to-book ratio sits below 1x.

Of total equity of KRW 159.2 billion at end-2025, KRW 139 billion belonged to controlling shareholders, so the share price is trading below that book value per controlling stake. This book value, however, reflects the profit and loss path after the 2024 loss.

The third-party share issuance in February 2026 applied the statutory maximum 10% discount and added shares, which diluted per-share value. The dividend yield is below the sector average, and the approval of interim dividends at the March 2026 general meeting is cited as a change in shareholder return policy.

The share cancellation reflected in the October 27, 2026 listing change reduced shares outstanding. Valuation direction will depend on the pace of earnings recovery and changes in the capital structure.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Continuity of revenue growth

Revenue rose for three straight years from 2023 to KRW 271.6 billion in 2025, the largest year of 2022–2025. Sales also grew in Q2 and Q3 2026, extending the growth trend on a quarterly basis.

Average utilization at the Ansan plant reached 98.33% in the first half of 2026, showing that production capacity is being used heavily.

Production built on blockbuster products

The top ten products, led by Pravicen, Mosapit 5 mg and Nexon 20 mg, account for 49.5% of consolidated production. The 87 products with confirmed 2025 output account for KRW 156.2 billion, or 76.8% of drug production, so the portfolio is spread across many items.

Improving financial structure

The debt ratio fell from 81.5% in 2024 to 61.9% in 2025, and operating cash flow recovered from KRW 1.79 billion in 2024 to KRW 11 billion in 2025. Controlling-shareholder equity is KRW 139 billion of total equity of KRW 159.2 billion.

The planned stake sale in the anticancer affiliate and the share issuance and convertible bond proceeds are aimed at reducing debt.

09

Bear factors

Lower margins and falling operating profit

Q3 2026 operating profit of KRW 1.66 billion was down 14.8% year on year, so revenue growth has not carried through to profit. The filed figures show margins narrowing even as sales rise.

Volatility in quarterly results

Q1 2026 operating profit of KRW 1.94 billion fell 54.1% quarter on quarter, and the controlling-shareholder net loss was KRW 3.74 billion. The 2024 controlling-shareholder loss of KRW 41 billion shows how wide the swings have been.

Price re-evaluation and product concentration

The first-round re-evaluation covers 116 insurance codes, which account for at least 76.8% of drug production, so the reach of any price adjustment is wide. Top products such as Pravicen carry large output, and Expera remains in later rounds. A separate price cut has also been reported, so pressure on individual product prices could weigh on results.

10

Risk factors

Drug price re-evaluation

The 116 first-round insurance codes each sit in a different ingredient group, which makes product-by-product compliance demanding. The covered products account for KRW 156.2 billion of 2025 output, or 76.8% of drug production. Later rounds could add Expera, which had KRW 10.8 billion of 2025 output, widening the scope.

Governance and share dilution

The February 2026 third-party share issuance went to the founder's son at the statutory maximum 10% discount. Yuhan, then the second-largest shareholder, expressed opposition, but the board approved the issuance. Minority shareholders objected to the dilution and to the lack of detail on how the funds would be used.

Execution of restructuring and capacity investment

The planned sale of the anticancer affiliate stake can improve the balance sheet, but its impact on profit depends on price and timing. Commercialization of the precision medicine business is cited as the key medium-term question. Plant expansion and a possible second factory will depend on financing and utilization.

11

What to watch next

  1. By March 31, 2027

    The 2026 annual report deadline will show fourth-quarter 2026 results, whether the annual operating margin moved from 3.8% in 2025, and how much debt was repaid with share and convertible bond proceeds.

  2. Around March 2027 (prior AGM held March 27, 2026)

    Whether the interim dividend approved in 2026 is actually paid, and how the board composition and outside director ratio change, can be checked at this meeting.

  3. After December 31, 2026 (timing not fixed)

    Completion of the anticancer affiliate stake sale, whether proceeds go to plant expansion, and the timing of later drug price re-evaluation rounds are the next points to watch.

12

Overall view

Theragen Etex's revenue rose for three straight years from 2023 to KRW 271.6 billion in 2025, but its operating margin fell from 5.4% in 2022 to 3.8% in 2025.

Net income attributable to controlling shareholders returned to KRW 10.6 billion in 2025, yet the last four quarters total a KRW 4.2 billion controlling-shareholder net loss, and quarterly profit keeps swinging.

Revenue grew in Q2 and Q3 2026 for two consecutive quarters, but Q3 2026 operating profit of KRW 1.66 billion was down 14.8% year on year. The debt ratio fell from 81.5% in 2024 to 61.9% in 2025, and the February 2026 share issuance and convertible bonds are funding debt repayment and facility investment.

Pharmaceutical operations make up most of consolidated revenue, and the first-round price re-evaluation, covering 76.8% of drug production, remains the largest variable.

Strengths include sales growth, high plant utilization and an improving financial structure, while weaknesses include margin compression, quarterly profit swings, the price re-evaluation and dilution concerns tied to governance.

The company has pointed to restructuring through the planned anticancer affiliate stake sale and a possible second factory, and the 2026 annual report will show how these play out.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. dailypharm.com
  2. m.dailypharm.com
  3. thevc.kr
  4. m.dailypharm.com
  5. pinpointnews.co.kr
  6. medicopharma.co.kr
  7. buffettlab.co.kr
  8. theragenetex.com
  9. v.daum.net
  10. news.nate.com
  11. topstarnews.net
  12. m.news.nate.com
  13. m.news.nate.com
  14. jasoseol.com
  15. pharm.edaily.co.kr
  16. m.sedaily.com
  17. kr.investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis